Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
Bastard P,Rosen L,Zhang Q,Michailidis E,Hoffmann H,Zhang Y,Dorgham K,Philippot Q,Rosain J,Béziat V,Manry J,Shaw E,Haljasmägi L,Peterson P,Lorenzo L,Bizien L,Trouillet-Assant S,Dobbs K,de Jesus A,Belot A,Kallaste A,Catherinot E,Tandjaoui-Lambiotte Y,Le Pen J,Kerner G,Bigio B,Seeleuthner Y,Yang R,Bolze A,Spaan A,Delmonte O,Abers M,Aiuti A,Casari G,Lampasona V,Piemonti L,Ciceri F,Bilguvar K,Lifton R,Vasse M,Smadja D,Migaud M,Hadjadj J,Terrier B,Duffy D,Quintana-Murci L,van de Beek D,Roussel L,Vinh D,Tangye S,Haerynck F,Dalmau D,Martinez-Picado J,Brodin P,Nussenzweig M,Boisson-Dupuis S,Rodríguez-Gallego C,Vogt G,Mogensen T,Oler A,Gu J,Burbelo P,Cohen J,Biondi A,Bettini L,D'Angio M,Bonfanti P,Rossignol P,Mayaux J,Rieux-Laucat F,Husebye E,Fusco F,Ursini M,Imberti L,Sottini A,Paghera S,Quiros-Roldan E,Rossi C,Castagnoli R,Montagna D,Licari A,Marseglia G,Duval X,Ghosn J,Tsang J,Goldbach-Mansky R,Kisand K,Lionakis M,Puel A,Zhang S,Holland S,Gorochov G,Jouanguy E,Rice C,Cobat A,Notarangelo L,Abel L,Su H,Casanova J
Source :
Pmid / DOI: